• USP42 Suppresses JNK/p38 Apoptosis in Breast Cancer

  2026-09-11

  The reference study identifies USP42 as a pro-tumorigenic deubiquitinating enzyme in breast cancer and links its depletion to activation of JNK/p38 signaling, apoptotic protein remodeling, and reduced tumor growth. Its combination of cellular assays, pathway inhibition, and xenograft validation provides a mechanistic framework for evaluating USP42 as a potential therapeutic target, while also defining important limits for translation.

• Nullscript as a Causal Probe in Placental Stress

  2026-09-11

  Nullscript is a histone deacetylase inhibitor with an unusual transcriptional inactivity profile. This article develops a causality-focused assay framework for testing whether HDAC activity intersects with the NMNAT3–NAD+–ferroptosis pathway described in placental nanoplastic toxicity.

• CDK9 inhibitor A3294: Practical Lab Workflow

  2026-09-10

  CDK9 inhibitor A3294 provides selective biochemical inhibition of cyclin-dependent kinase 9 for studies of transcription elongation and HIV-1 propagation. It is appropriate for targeted CDK9 experiments, but not for pan-CDK inhibition, broad cell-cycle studies, or workflows requiring long-term storage of prepared solutions.

• Dabigatran etexilate: Assay Workflow Guide

  2026-09-10

  A scenario-based guide to using Dabigatran etexilate (SKU A8381) in thrombin, plasma coagulation, and cell-assay control workflows. It explains concentration planning, solvent compatibility, interpretation limits, and practical supplier-selection criteria for reproducible anticoagulant research.

• Dabigatran etexilate: Assays and Workflows

  2026-09-09

  Build more reproducible thrombin, plasma coagulation, and platelet assays with a practical workflow for Dabigatran etexilate. The guide distinguishes prodrug handling from active-inhibitor testing while connecting direct thrombin inhibition to atrial fibrillation research and translational assay design.

• CLEC5A, ISG20, and Atherosclerosis Causality

  2026-09-09

  This 2025 study integrates GEO transcriptomics, eQTL evidence, Mendelian randomization, and experimental validation to examine whether CLEC5A and ISG20 are causally associated with atherosclerosis. Its strongest translational signal is the reproducible elevation of ISG20 in ox-LDL-stimulated macrophages, ApoE-deficient mice, and plaque regions enriched in endothelial cells and macrophages.

• AEBSF.HCl in Lysosome–Necroptosis Assays

  2026-09-08

  AEBSF.HCl is a broad-spectrum serine protease inhibitor that can sharpen necroptosis and protease assay interpretation. This guide distinguishes serine-protease effects from MLKL-driven lysosomal cathepsin release and translates that distinction into practical experimental design.

• PPACK Dihydrochloride as a Thrombin Control

  2026-09-08

  PPACK Dihydrochloride enables mechanistic separation of thrombin-dependent platelet responses from P2-receptor signaling. This article integrates covalent enzyme inhibition with evidence from a landmark NF449 study to improve assay design, interpretation, and translational relevance.

• Gastrin I for Gastric Acid Secretion Research

  2026-09-07

  Gastrin I provides a controllable CCK2 receptor stimulus for dissecting gastric acid secretion, proton pump activation, and receptor-linked signaling in cell-based assays. This guide combines practical peptide handling with organoid-informed model selection, helping researchers connect focused gastric experiments with broader gastrointestinal physiology studies.

• Rapamycin (Sirolimus) for mTOR Research

  2026-09-07

  Rapamycin (Sirolimus) provides a practical pharmacological handle for testing how mTOR activity influences autophagy, tumor-cell behavior, and metabolic stress. This guide connects the compound to the PTK6–SOCS3 findings in uveal melanoma while emphasizing dose design, orthogonal readouts, and troubleshooting.

• Tofacitinib Rewires RA Macrophage Dysfunction

  2026-09-05

  A translational analysis of how Tofacitinib, also known as CP-690550, moves beyond conventional cytokine suppression by reversing GM-CSF-driven inflammatory, STAT5-associated, and mitochondrial defects in rheumatoid arthritis macrophages.

• Tofacitinib Workflows for RA Macrophage Research

  2026-09-04

  Tofacitinib (CP-690550) helps researchers dissect JAK/STAT-dependent inflammation, GM-CSF-driven macrophage activation, and mitochondrial stress in rheumatoid arthritis models. This guide translates the latest RA macrophage findings into practical assay workflows, dosing logic, controls, and troubleshooting strategies.

• Tofacitinib (CP-690550) and RA Macrophage Repair

  2026-09-04

  A translational perspective on how Tofacitinib links JAK/STAT pathway control with inflammatory and mitochondrial-state correction in GM-CSF-reprogrammed rheumatoid arthritis macrophages.

• Sulfo-NHS-LC-Biotin: Practical Labeling Guide

  2026-09-03

  Sulfo-NHS-LC-Biotin is a water-soluble reagent for stable covalent biotinylation of primary amines on proteins, peptides, and intact-cell surface proteins. It is suited to biotin-avidin or streptavidin capture workflows, but not to intracellular labeling or reversible modification.

• XG005 and Somatic Mutations in SARS-CoV-2 Neutralization

  2026-09-03

  The Cell Reports study shows that fortuitous somatic mutations can transform one member of an antibody family into XG005, a potent and broadly neutralizing antibody against SARS-CoV-2 variants, including Omicron sublineages. Structural comparison, antibody engineering, and mouse challenge experiments connect specific sequence changes with neutralization breadth and therapeutic performance.

8631 records 1/576 page Next 12345 下5页 Last page